menu
    • menu
    [{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Therapeutics \/ Omega Funds"}]

    Find Clinical Drug Pipeline Developments & Deals by Chord Therapeutics

    Menu

    Chord Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chord Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chord Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

                            Details : The company entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a company focused on rare neuroinflammatory diseases. Acquisition provides opportunity to develop cladribine in Myasthenia Gravis and Neuromyelitis Optica ...

                            Product Name : Mavenclad

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 20, 2021

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chord Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Chord Therapeutics

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : Omega Funds

                            Deal Size : $16.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Chord Therapeutics Launches with USD 16 million Series A Financing

                            Details : The financing will allow the company to progress CRD1 through Phase 2 proof of concept clinical development. The potential of CRD1 to address unmet medical needs in rare autoimmune disorders was identified by Chord Therapeutics‘ founder, Dr. Arthur Roa...

                            Product Name : Mavenclad

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 13, 2020

                            Lead Product(s) : Cladribine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : Omega Funds

                            Deal Size : $16.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth